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Introduction. Patients with multiple recurrences of well-diﬀerentiated thyroid carcinoma (WDTC) have markedly reduced overall
survival when compared with those who have ≤1 recurrence of their disease. The purpose of this investigation is to identify
prognostic factors for mortality in this subgroup. Methods. Patients with multiple recurrences of WDTC were retrospectively
identiﬁedfromthethyroidcancerdatabaseatMountSinaiHospital,Toronto(1963–2000).Dataonpatient,tumor,andrecurrence
characteristics were collected, and each patient was given aMACIS score. Results. A total of 31 patients were identiﬁed (11 male, 20
female;16–83years).Usingunivariateanalysis,age>45,stageIII/IVdisease,distantmetastasis,vascularinvasion,MACISscore>6,
and time to recurrence of <12 months were found to be signiﬁcant predictors for mortality in this subgroup. Conclusions. Patients
with multiple recurrences of WDTC follow a distinct clinical course, marked with multiple treatment failures and a substantial
risk of mortality.
Copyright © 2009 Theresa Holler et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Although well-diﬀerentiated thyroid carcinoma (WDTC)
is the most commonly diagnosed thyroid malignancy, it
accounts for only 2% of all cancers in the body and is
responsible for less than 0.5% of cancer-related deaths [1].
Combination therapy with thyroidectomy and adjuvant I131
is the treatment of choice at most institutions. The majority
of patients have an excellent prognosis, with disease-speciﬁc
survivalratesat10yearsgreaterthan90%[1].However,8%–
23% of patients will fail initial therapy and go on to develop
a recurrence of their disease [1–4]. Mortality rates among
patients with disease recurrence have been reported to be as
high as 38%–69% [4–6] .I nap r e v i o u ss t u d y ,P a l m ee ta l .[ 7]
showedthatWDTCpatientswhohadeithernorecurrenceof
their disease or only one recurrence after initial therapy had
no diﬀerence in disease-speciﬁc or overall survival (100%
versus 94%, 89% versus 83%, resp.). In addition, patients
with multiple treatment failures had signiﬁcantly reduced
survivals (60% and 58%, resp., P<. 001).
There has been a large body of research compiled over
the past few decades examining various prognostic factors
for both recurrence and mortality in patients with WDTC.
F a c t o r ss u c ha sa g e>45, male sex, large tumor size, histolog-
ical type, advanced stage of disease, extrathyroidal extension,
lymphatic invasion, and presence of distant metastasis have
all been cited as indicators of poor outcome [1–4, 6, 8–20].
Several groups have attempted to classify patients into low-,
intermediate-, and high- risk groups based on the presence
of these factors [10, 17]. Prognostication is therefore used to
identify patients at high risk who require close follow-up and
prompt therapy for any evidence of disease recurrence. To
our knowledge, there are no reports in literature delineating
prognosticfactorstopredictdiseaseoutcomeinpatientswho
have suﬀered with multiple treatment failures of WDTC.
Thus, the purpose of this investigation is to examine patient,
tumor, treatment, and recurrence factors that may predict
for mortality among patients with multiple recurrences of
WDTC.
2.MaterialsandMethods
Thirty-one patients with multiple recurrences of WDTC
were retrospectively identiﬁed from the thyroid cancer2 Journal of Oncology
database at Mount Sinai Hospital, Toronto (1963–2000).
Recurrence was deﬁned as any evidence of disease requiring
further treatment after initial curative therapy. Patient
(age, sex), tumor (histology, size, stage, solitary/multifocal,
extrathyroidal spread, vascular invasion, lymphatic inva-
sion), and treatment (extent of initial surgery, adjuvant
I131, and external beam radiation) characteristics were
collected. Information about the site of each recurrence
(local, regional, distant, unspeciﬁed), mode of detection
(clinical, imaging, thryoglobulin estimation), and treatment
(surgery, I131 therapy) were also recorded. Extent of disease
at presentation was staged according to the American Joint
Committee on Cancer (AJCC) staging system for WDTC
[21]. In addition, each patient was scored according to the
Metastasis, Age, Completeness of Resection, Invasion, and
Size (MACIS) prognostic index [22]. Extent of initial surgery
was recorded as either a subtotal or total thyroidectomy with
or without an accompanying neck dissection. A recurrence
was classiﬁed as unspeciﬁed if thyroglobulin levels were
elevated in the presence of a negative clinical exam and
failure of localization with available imaging modalities
(i.e., ultrasonography, I131 scanning, CT, and MRI). Final
outcome was recorded as alive, no evidence of disease
(ANED), alive with disease (AWD), dead, no disease (DND),
and dead of disease (DOD). Follow-up was counted from
completion of initial therapy to the last known clinical
encounter or date of death.
Statistical analysis of survival data was performed using
the Kaplan-Meier method, and curves were compared using
the log-rank test. P<. 05 was considered statistically
signiﬁcant. Univariate analysis was performed in order to
identify prognostic factors signiﬁcant for the development
of a poor outcome (i.e., death) in patients with multiple
recurrences of WDTC. Multivariate analysis using the Cox
proportional hazards model was not possible due to the
limited number of events in this study. All statistics were
carried out using SPSS software (SPSS Inc, Chicago, Ill).
3. Results
Thirty-one patients with multiple recurrences of WDTC
were identiﬁed from treatment records at the Department
of Otolaryngology — Head & Neck Surgery, Mount Sinai
Hospital (Toronto), with a median follow-up of 12.6 years
(range 9 months–35.5 years). There were 20 (64.5%) female
patients and 11 (35.5%) male patients (median age 43, range
16–83 years; Table 1). The ﬁnal histopathologic diagnosis
was papillary carcinoma in 19 (61.3%), tall cell variant in
5 (16.1%), follicular carcinoma in 4 (12.9%), and mixed in
3 (9.7%) cases. The median size of the dominant nodule
was 3.3cm (range 0.5–5.5cm). Seven of the charts did not
contain a report of tumor size and thus could not be scored
with the MACIS prognostic index. These patients were
excluded from further analysis. Of the 31 patients identiﬁed,
6 (19.4%) had evidence of distant metastasis at diagnosis.
Other tumor characteristics present at ﬁrst surgery included
multifocal disease in 21 (67.7%) patients, extrathyroidal
spread in 18 (58.1%) patients, lymphatic invasion in 18
Table 1: Demographic data for patient with multiple recurrences
of well-diﬀerentiated thyroid carcinoma.
N3 1
Age, median (range), years 43 (16–83)
Sex, M:F 11:20
Histologic type
Papillary 19
Follicular 4
Mixed 3
Tall cell 5
Tumour size, median (range), cm 3.3 (0.5–5.5)
Multifocal disease 21
Extrathyroidal extension 18
Lymphatic invasion 18
Vascular invasion 3
Distant metastasis 6
AJCC stage
I4
II 8
III 11
IV 8
MACIS, median (range) 6.03 (3.25–11.02)
Extent of initial surgery
Subtotal thyroidectomy 12
Total thyroidectomy 19
Neck dissection† 15
Lodine 131 therapy 27
External beam radiation therapy 10
Site of recurrence
Local 6
Regional 15
Distant 6
Unspeciﬁed 4
Outcome
Alive, no evidence of disease 9
Alive with disease 12
Dead of disease 10
Dead, no evidence of disease 0
Follow–up, median (range), years 12.6 (9months35.5years)
AJCCAmerican JOINT Committee on Cancer.
Data is for the number of patients in each category.
†central +/- lateral neck dissection.
Unspeciﬁed recurrence-elevated thyroglobulin levels in the presence of a
negative clinical exam and failure of localization with imaging modalities
(i.e., ultrasonography, I131 scanning, CT and MRI).
(58.1%) patients, and vascular invasion in 3 (9.7%) patients.
According to the AJCC staging system, Stage I disease was
present in 4 patients (12.9%), Stage II in 8 patients (25.8%),
Stage III in 11 patients (35.5%), and Stage IV in 8 patients
(25.8%). The MACIS prognostic index was applied to 24
cases in the series with complete pathology records (median
score 6.03, range 3.25–11.82).Journal of Oncology 3
Extent of initial surgery was dependent on both disease
severity and the prevailing treatment philosophy at the
time of diagnosis. A total thyroidectomy was performed
in 19 (61.3%) patients, whereas a subtotal thyroidectomy
was performed in 12 (38.7%) cases. A neck dissection
accompanied thyroidectomy in 15 patients with evidence of
nodal metastasis at initial surgery. Almost all patients in this
series were treated with adjuvant I131 (87.1%). Ten patients
had residual disease severe enough after initial operation to
warrant external beam radiation therapy (ERT).
All patients in this series experienced multiple treat-
ment failures. The average time to ﬁrst recurrence was
25.4 months (range 0.2–185.4 months). Recurrences were
classiﬁedaslocal(19.4%),regional(48.4%),distant(19.4%),
and unspeciﬁed (12.9%). Neither the mode of detection (i.e.,
clinical, imaging, or elevated thyroglobulin) nor the method
of treatment (surgery, I131, or ERT) for recurrent disease was
found to be a signiﬁcant predictor of survival in this study
population.
Thirty-two percent of patients with multiple recurrences
of WDTC died of their disease (DOD). Other outcomes
included alive, no evidence of disease (ANED) in 29% and
alive with disease (AWD) in 38.7%. No patients in this series
died of causes unrelated to their thyroid carcinoma. Actuar-
ially predicted disease-speciﬁc survival among patients with
multiple treatment failures at 20 years was 60%, a signiﬁcant
reduction from that of patients with either no recurrences or
only one recurrence of their disease [7]. Univariate analysis
revealed that age >45, stage III/IV disease, distant metastasis,
vascular invasion, MACIS score >6, and a time to recurrence
of <12 months are all predictive factors for mortality in
this group (P<. 01,<. 01,<. 001,<. 001,<. 01, <. 03,
resp.; Figure 1). In addition, gender, histological type, initial
surgery (total thyroidectomy vs. subtotal thyroidectomy),
initial I131therapy, multifocal disease, tumor size, lymphatic
invasion, and neck dissection were shown to have no
predictive utility in this subgroup of patients with WDTC
(Table 2).
4. Discussion
Despite optimal treatment, patients with WDTC often expe-
rience disease recurrence, with rates reported in literature
ranging from 8% to 23% [1–4]. Palme and associates
[7], reported no signiﬁcant diﬀerence in disease speciﬁc
and overall survival among WDTC patients cured after
initial therapy, and those with a single recurrence. However,
patients with multiple recurrences are at a signiﬁcantly
increased risk of death, with mortality rates ranging between
12% and 69% [2, 4–6]. It appears that patients who develop
multiple recurrences of WDTC follow a distinct course,
marked by multiple treatment failures and a signiﬁcant risk
of mortality. It was the intention of the present study to
delineate patient, tumor, treatment, and recurrence factors
that may be used by physicians to predict for mortality in
these patients.
A large body of research exists exploring various prog-
nostic factors for recurrence and mortality among patients
Table 2: Patient, tumour, treatment, and recurrence data for
patients with multiple recurrences of well-diﬀerentiated thyroid
carcinoma.
Age > 45 ∗∗P = .0093
Gender (M Versus F) P = .7876
Extent of initial surgery (ST versus TT) P = .0964
Neck dissection P = .1978
Iodine 131 therapy P = .1749
External beam radiation therapy ∗P = .0167
Histologic type—overall P = .1362
Tall cell versus others †P = .0748
Stage I/II versus IV ∗∗P = .0052
Size > 4cm †P = .0621
Multifocal disease †P = .0795
Lymphatic invasion P = .9361
Vascular invasion ∗∗∗P = .0002
Extrathyriodal extention †P = .0772
Distant metastasis ∗∗∗P = .0002
MACIS > 6 ∗∗P = .0061
Time to recurrence < 12 months ∗P = .0270
Site of recurrence †P = .0560
Mode of detection
Clinical P = .6328
Imaging P = .5752
Thyroglobulin P = .7497
Treatment of recurrence
Surgery P = .4128
Iodine 131 therapy P = .6281
External beam radiation therapy P = .8889
ST: subtotal thyroidectomy; TT: total thyroidectomy
∗P<. 05; ∗∗P<. 01; ∗∗∗P<. 001
† trend toward signiﬁcance.
with WDTC. Characteristics such as age, sex, tumor size,
stage, extrathyroidal spread (ETS), nodal metastases, distant
metastases, and extent of initial surgery have all been cited
as indicators of poor outcome [1–4, 6, 8–20]. In this
investigation, we found that among patients with multiple
treatment failures, age >45, stage III/IV disease, distant
metastasis, vascular invasion, MACIS score >6, and a time to
recurrence of <12 months predicted mortality in this group.
Several studies have cited advanced age as being one of
the most signiﬁcant predictors for recurrence and mortality
among patients with WDTC. Shah et al. [8] reported that
patients above the age of 50 have a 270% greater risk of
death from diﬀerentiated thyroid cancer than their younger
cohorts. In addition, several authors have cited that the
greatest change in prognosis occurs at the age of 45, with
older patients having signiﬁcantly reduced total survival
[6, 8–13]. This is in agreement with the results of the current
study; patients with multiple recurrences of WDTC who are
older than 45 years of age are at an increased risk of death
from their disease (P<. 01).4 Journal of Oncology
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Figure 1: Prognostic factors signiﬁcantly associated with mortality in patients with multiple recurrences of well-diﬀerentiated thyroid
carcinoma. (a). age >45, (b). stage III/IV disease, (c). angioinvasion, (d). distant metastasis, (e). MACIS score >6, (F). time to recurrence
<12 months.
Extent of disease at initial diagnosis strongly inﬂuences
prognosis in patients with WDTC. Large tumor size, espe-
cially >4cm, has been shown to adversely aﬀect mortality in
multiple trials [9–11, 14]. Although greater tumor size (i.e.,
>4cm) was found to be a predictor of multiple recurrences
in patients with WDTC [7], it did not appear to predict for
mortality in this population.
The AJCC staging system, which incorporates the TNM
(tumor, lymph nodes, metastases) classiﬁcation, is the
current standard in staging thyroid malignancies. Stage
III/IV disease (III = ETS or nodal metastases, IV = distant
metastases) appears to portend an increased risk of mortality
among patients with multiple recurrences of WDTC. This
is in agreement with other authors, who have found that
advanced stage disease not only increases the risk of recur-
rence but aslo signiﬁcantly reduces disease-speciﬁc survival
[7–9, 12, 13, 15]. In the present study, there appears to be a
trend toward signiﬁcance for the adverse eﬀect of extrathy-
roidal extension (T3) on mortality (P = .07). In addition,
we found that neither lymphatic invasion nor initial neck
dissection showed a statistical signiﬁcance for mortality
among patients with WDTC. However, the presence of
vascular invasion did appear to portend a poor prognosis on
survival in this cohort (P = .002). Lastly, distant metastases
were found to be a highly signiﬁcant predictor of mortality
among patients with multiple recurrences of WDTC (P =
.0002).
Patients who have their ﬁrst treatment failure <12
months after initial therapy appear to have signiﬁcantly
shorter survival than those who recur after one year. The
median time to ﬁrst recurrence in the present study was
7.3 months, with one patient not showing evidence of
any treatment failure until more than 15 years after initial
surgery. Given the extensive length of time which may pass
between initial treatment and recurrence, life-long follow up
is necessary.
Several authors have shown that both the method of
detection and the treatment modality used for a ﬁrst
recurrence can predict future treatment failures [7, 20]. That
is, patients who have clinically detectable disease recur at a
greater rate than those whose ﬁrst recurrence is detected by
thyroglobulin measurement or imaging modalities, stressing
the need for early detection before tumor burden becomes
signiﬁcant. In the present investigation, neither the method
of detection (i.e., clinical, imaging, I131, thyroglobulin)
nor the treatment modality (surgery, I131,e x t e r n a lb e a m
radiotherapy) inﬂuenced the mortality rates among patients
with multiple treatment failures of WDTC.Journal of Oncology 5
Because both multiple recurrences and mortality from
WDTC are a rare event, it was necessary in the present
study to collect data over several decades. In 37 years of
clinical experience treating WDTC at our institution, only
31 patients were identiﬁed as having multiple recurrences
of their disease. Of these, only 10 patients died from their
disease. In addition, it is well known that patients with
WDTC can be free from disease for many years before
developingaﬁrstrecurrence,aphenomenonthatnecessitates
life-long follow-up in these patients. The long duration of
follow-up in the present study allows for the identiﬁcation
of disease recurrences as well as an assessment of long-term
clinical outcomes.
Despite changing treatment paradigms over the 4
decades analyzed in this study, all 10 patients who died of
their disease had both surgical and adjunctive management
of their initial disease that is comparable to current practices
at our institution. All patients with advanced stage WDTC
underwent either a total thyroidectomy (n = 8) or a
completion thyroidectomy at the time of initial diagnosis
(n = 2). Those with unresectable gross residual disease
were treated with external beam radiation therapy. Patients
who were considered to have microscopic residual disease or
whohadadvancedstagediseaseweregivenpostoperativeI131
ablation. In 2002, Hay et al. reported 6 decades of experience
treatingpapillarythyroidcarcinoma.Theyfoundthatdespite
evolving treatment paradigms, there was no diﬀerence in
overall survival among patients treated with subtotal versus
total thyroidectomy and no survival beneﬁt to postoperative
I131 ablation in low-risk patients (MACIS score <6) [23].
Given this, it is unlikely that changing treatment paradigms
has signiﬁcantly inﬂuenced the validity of the current results.
5. Conclusions
To our knowledge, this is the ﬁrst paper to identify
prognostic factors among patients with well-diﬀerentiated
thyroid carcinoma who suﬀer multiple recurrences of their
disease; patients with multiple recurrences of WDTC follow
a poor clinical course, with multiple treatment failures and
decreased survival. Among this subgroup, those aged 45
years or more with aggressive primary tumors (ETS and
vascular invasion) and advanced stage disease (Stage III/IV,
MACIS>6) have a signiﬁcantly higher risk of mortality. In
addition, time to ﬁrst recurrence within 12 months of initial
therapy conveys a worse prognosis. Interestingly, mortality
rates in this study were not inﬂuenced by the method of
detectionnorthetypeoftherapychosenforﬁrstrecurrences.
One potential explanation is that these patients have a
more biologically aggressive variant of WDTC which does
not readily respond to treatment of the primary tumor or
the initial recurrence. Although the failure to cure these
cases after several attempts may cause frustration in both
the treating physician and the patient, close follow-up and
aggressive treatment of further recurrences is still warranted,
as approximately 30% of these will go on to be free of disease
after subsequent therapies. Further research is needed into
the biological and molecular markers of tumor severity in
order to provide an understanding of why some patients
with WDTC have an excellent prognosis with complete cure,
while others are plagued by multiple treatment failures and
eventual death.
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